Immediate Impact
20 standout
Citing Papers
Alzheimer disease blood biomarkers: considerations for population-level use
2024 Standout
Pathogenesis, diagnostics, and therapeutics for Alzheimer's disease: Breaking the memory barrier
2024 Standout
Works of T. Bittner being referenced
Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force
2023
P32 Phase III studies of crenezumab in early (prodromal-to-mild) Alzheimers disease (CREAD/CREAD2): Biomarker results
2020
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| T. Bittner | 1 | 14 | 10 | 4 | 2 | 16 | ||
| Ketil Joachim Ødegaard | 1 | 6 | 15 | 3 | 3 | 25 | ||
| Kilian Kleemann | 3 | 1 | 11 | 4 | 3 | 3 | 20 | |
| Theresa Heath | 1 | 5 | 4 | 3 | 4 | 11 | ||
| Martin Farlow | 1 | 4 | 6 | 5 | 2 | 15 | ||
| Patricio Chrem | 2 | 9 | 19 | 3 | 23 | |||
| Valerie M. Wilson | 1 | 1 | 4 | 7 | 2 | 16 | ||
| Antti Jula | 1 | 6 | 6 | 2 | 3 | 16 | ||
| Bernadett Halda-Kiss | 12 | 2 | 9 | 7 | 1 | 3 | 21 | |
| Fatima Mitsie Chibana Soares | 9 | 5 | 1 | 2 | 22 | |||
| Stephanie J. B. Vos | 1 | 6 | 6 | 2 | 11 |
All Works
Loading papers...